Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer

This study evaluates the efficacy and safety of camrelizumab, apatinib, and eribulin versus physician's choice chemotherapy in advanced TNBC.Primary Objectives: Assess improvements in progression-free survival (PFS) and overall survival (OS).Secondary Objectives: Compare objective response rate (ORR), disease control rate (DCR), clinical benefit rate (CBR), duration of response (DoR), time to response (TTR), two-year OS rate, biomarker analysis, and quality of life (QoL).Safety: Assess and compare adverse event incidence and severity.

Trial Details

NCT ID
NCT06889688
Phase
PHASE3
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • Camrelizumab+Apatinib+Eribulin
  • Physician's choice chemotherapy
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guiyang, Guizhou, China|26.58333,106.71667
  • Wuhan, Hubei, China|30.58333,114.26667
  • Yichang, Hubei, China|30.71444,111.28472
  • Changsha, Hunan, China|28.19874,112.97087

Key Eligibility Criteria

  • The subject voluntarily agrees to participate in this study and signs an informed consent form (ICF).
  • Female subjects aged ≥18 and ≤70 years on the date of signing the ICF.
  • Pathologically confirmed advanced triple-negative breast cancer (TNBC), defined as ER-negative (IHC ER-positive percentage \<1%), PR-negative (IHC …
  • Patients who have received at least 1 and up to 4 lines of prior systemic therapy for metastatic or locally advanced unresectable triple-negative b…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →